Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study

Transplantation Proceedings
B CharpentierSirolimus European Renal Transplant Study


In 11 European centers, first cadaveric renal allograft recipients were randomized to CsA (n = 42) or sirolimus (n = 41). Dosing of these agents was concentration-controlled and open-labeled. All patients received corticosteroids and azathioprine. At 12 months, graft survival (98% sirolimus vs 93% CsA), patient survival (100% vs 98%), and incidence of biopsy-confirmed acute rejection (41% vs 38%) were similar. Serum creatinine was lower with sirolimus, significantly (P </=.05) so at 3 and 4 months, and serum uric acid and magnesium were normal. Laboratory abnormalities were reported significantly more often with sirolimus, which included hypertriglyceridemia (51% vs 12%), hypercholesterolemia (44% vs 14%), thrombocytopenia (37% vs 0%), leukopenia (39% vs 14%), and, of lesser importance, increased liver enzymes and hypokalemia. These abnormalities improved 2 months after transplantation when the sirolimus target trough level was lowered from 30 to 15 ng/mL. Occurrence of cytomegalovirus was comparable (14% vs 12%), but incidence of herpes simplex (24% vs 10%, P =.08) and pneumonia (17% vs 2%, P =.03) were higher with sirolimus. No gingival hyperplasia was seen with sirolimus, tremor was rare, and hypertension was less frequent (...Continue Reading


Mar 1, 1992·Transplantation·J F DiJosephJ Y Chang
Jun 27, 1995·Transplantation·B J NankivellJ R Chapman
Oct 1, 1996·Kidney International·W M BennettJ M Barry
Oct 27, 1996·Transplantation·J F DiJosephS N Sehgal
Dec 10, 1998·Transplantation·P H KrebsbachP G Robey

❮ Previous
Next ❯


Aug 9, 2013·Paediatric Drugs·D ThangarajahA Dhawan
May 28, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Kathleen ClaesHenrik Ekberg
Jan 22, 2005·Seminars in Nephrology·Marilda Mazzali
Aug 31, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·C A GleissnerT J Dengler
Sep 15, 2012·The Journal of Dermatology·Monji KogaJuichiro Nakayama
Jul 14, 2010·Artificial Organs·Berna YelkenMehmet S Sever
May 24, 2015·Transplantation Reviews·Steven Van Laecke, Wim Van Biesen
Apr 26, 2005·Transplantation Proceedings·J P IbáñezA Turconi
Jun 2, 2007·Colloids and Surfaces. B, Biointerfaces·C J PanN Huang
Dec 21, 2010·Transplantation Proceedings·M del Carmen RialJ Alberú
Sep 27, 2005·Transplantation Proceedings·B ParadaA Figueiredo
Sep 2, 2004·Respiratory Medicine·David ShitritMordechai R Kramer
Sep 1, 2016·Health Technology Assessment : HTA·Tracey Jones-HughesRob Anderson
Oct 7, 2004·Journal of the American College of Cardiology·Ron WaksmanUNKNOWN Oral Rapamune to Inhibit Restenosis study
Aug 2, 2014·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·Yehui ChenZhiwei Zhang
Sep 9, 2008·Transplant Immunology·Dela Golshayan, Manuel Pascual
Dec 17, 2019·The Cochrane Database of Systematic Reviews·Deirdre HahnAngela C Webster
Jul 24, 2012·Transplant International : Official Journal of the European Society for Organ Transplantation·Josep GrinyoNassim Kamar
Apr 18, 2017·Cell and Tissue Research·Alexander Kuczkowski, Paul T Brinkkoetter
Sep 27, 2018·Journal of Vascular Surgery·Biao ZhouWei Kong
Feb 27, 2016·Transplantation Proceedings·D Q ZhaoQ Q Sun
Apr 28, 2004·Transplantation Proceedings·T RampinoA Dal Canton

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.